|
No.
|
Drug-indication pair
|
Indication uniqueness
|
Disease rarity
|
Disease severity
|
Adv.tech.
|
Manufacturing technology
|
Therapeutic alternative
|
Sci. evid. clin.eff
|
Benefits from use of medicine
|
Cost effectiveness
|
Budget impact
|
Total number of points
|
|---|
| |
THRESHOLD
|
75 %
| | | | | | | | | |
15 points
|
|
1
|
Nexavar (HCC)
|
1
|
2
|
2
|
0
|
2
|
2
|
2
|
0
|
1
|
1
|
13
|
|
2
|
Nplate
|
2
|
1
|
0
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
13
|
|
3
|
Cystadane
|
2
|
2
|
2
|
0
|
0
|
2
|
0
|
2
|
0
|
2
|
12
|
|
4
|
Increlex
|
2
|
0
|
0
|
2
|
2
|
2
|
1
|
1
|
0
|
2
|
12
|
|
5
|
Revlimid (MM/S)
|
1
|
0
|
2
|
1
|
0
|
2
|
2
|
1
|
1
|
2
|
12
|
|
6
|
Yondelis
|
1
|
1
|
2
|
2
|
0
|
2
|
2
|
0
|
1
|
0
|
11
|
|
7
|
Somavert
|
2
|
1
|
1
|
2
|
2
|
0
|
1
|
1
|
1
|
0
|
11
|
|
8
|
Tasigna
|
2
|
2
|
2
|
0
|
0
|
2
|
1
|
1
|
0
|
0
|
10
|
|
9
|
Torisel
|
1
|
0
|
2
|
2
|
2
|
0
|
1
|
1
|
0
|
1
|
10
|
| |
THRESHOLD
|
50 %
| | | | | | | | | |
10 points
|
|
10
|
Vidaza
|
1
|
0
|
2
|
1
|
0
|
0
|
2
|
1
|
1
|
0
|
8
|
|
11
|
Atriance
|
1
|
0
|
2
|
1
|
0
|
2
|
1
|
0
|
0
|
1
|
8
|
|
12
|
Nexavar (RCC)
|
1
|
0
|
2
|
0
|
2
|
1
|
2
|
0
|
0
|
0
|
8
|
| |
THRESHOLD
|
25 %
| | | | | | | | | |
5 points
|
-
Adv. tech. Advancement of technology, Sci. evid. clin. eff. scientific evidence for clinical efficiency, NA no data available, HCC Hepatocellular carcinoma, GIST Malignant gastrointestinal stromal tumors, MM/S Myeloproliferative syndrome, DFSP Dermatofibrosarcoma protuberans, RCC Renal cell carcinoma, MM Multiple myeloma, ALL Ph+ Philadelphia chromosome positive chronic myeloid leukemia, MDS/MPD Myelodysplastic/myeloproliferative diseases
